Call for Abstracts

The lymphoma symposium will be devoted to “Novel frontiers in molecular diagnosis of lymphoma: biomarkers and integrative prognostic models”.

It will explore the plethora of new technologies that help us understand lymphoma biology and are key to pathological classification, and how best to integrate them into our daily clinical practice. The clinical impact of innovative technologies in the management of lymphoma patients will be discussed. In addition, there will be a session on lymphoma entities that are defined by structural chromosomal alterations and the significance of secondary translocations in classification algorithms.

Topics to be reviewed include:

• New horizons in clonality detection
• NGS clonality in routine diagnoses
• The significance of somatic mutations for lymphoma diagnosis and recurrence
• The role of NGS panel sequencing in a routine diagnostic setting will also be explored,
• Algorithms for data evaluation
• Molecular classification of aggressive B-cell, T-cell and low-grade B-cell lymphomas

Abstract submission subject headings

• Clonality analysis and the role of NGS
• NGS panels for diagnosis, including molecular algorithms
• Structural chromosomal alterations in lymphoma
• The clinical impact of innovative technologies in the management of lymphoma patients
• Other topics including recent advances

The bone marrow symposium will be focused on “Novel frontiers in molecular diagnosis of myeloid neoplasms: biomarkers and integrative prognostic models in myeloid diseases” the aim is to understand how a proper integration of morphological, clinical and molecular data is essential in reaching a correct diagnosis and to guide treatment decision.

Topics to be discussed will include the prognostic and clinical significance of new genetic markers or combinations of genetic markers, the paradigm of targeting oncogenic tyrosine kinase signaling in myeloid neoplasia, and the importance of doing genetic analysis in unusual presentation of myeloid diseases or as marker of disease progression.

Abstracts that will complement these topics will be mainly considered but original studies in any area of myeloid malignancy will also be evaluated for platform presentation or in the “poster sessions”.

Abstract submission subject headings

−          myeloid neoplasms with multiple mutations (evolving over time)

−          disease categories with molecular markers of disease progression

−          NGS panels for diagnosis, including molecular algorithms

The abstracts will be reviewed and selected by the scientific committee. Notifications will be sent to the authors via email no later than two weeks before the closure of the early bird registration for the meeting.